vs

Side-by-side financial comparison of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and PHOTRONICS INC (PLAB). Click either name above to swap in a different company.

ARROWHEAD PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($264.0M vs $210.4M, roughly 1.3× PHOTRONICS INC). ARROWHEAD PHARMACEUTICALS, INC. runs the higher net margin — 11.7% vs 10.9%, a 0.8% gap on every dollar of revenue. On growth, ARROWHEAD PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (10461.3% vs -5.5%). PHOTRONICS INC produced more free cash flow last quarter ($25.2M vs $11.3M).

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.

ARWR vs PLAB — Head-to-Head

Bigger by revenue
ARWR
ARWR
1.3× larger
ARWR
$264.0M
$210.4M
PLAB
Growing faster (revenue YoY)
ARWR
ARWR
+10466.8% gap
ARWR
10461.3%
-5.5%
PLAB
Higher net margin
ARWR
ARWR
0.8% more per $
ARWR
11.7%
10.9%
PLAB
More free cash flow
PLAB
PLAB
$13.9M more FCF
PLAB
$25.2M
$11.3M
ARWR

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
ARWR
ARWR
PLAB
PLAB
Revenue
$264.0M
$210.4M
Net Profit
$30.8M
$22.9M
Gross Margin
33.7%
Operating Margin
15.5%
22.9%
Net Margin
11.7%
10.9%
Revenue YoY
10461.3%
-5.5%
Net Profit YoY
117.8%
-32.4%
EPS (diluted)
$0.22
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARWR
ARWR
PLAB
PLAB
Q4 25
$264.0M
Q3 25
$210.4M
Q2 25
$211.0M
Q1 25
$212.1M
Q4 24
$222.6M
Q3 24
$211.0M
Q2 24
$217.0M
Q1 24
$216.3M
Net Profit
ARWR
ARWR
PLAB
PLAB
Q4 25
$30.8M
Q3 25
$22.9M
Q2 25
$8.9M
Q1 25
$42.9M
Q4 24
$33.9M
Q3 24
$34.4M
Q2 24
$36.3M
Q1 24
$26.2M
Gross Margin
ARWR
ARWR
PLAB
PLAB
Q4 25
Q3 25
33.7%
Q2 25
36.9%
Q1 25
35.6%
Q4 24
37.0%
Q3 24
35.6%
Q2 24
36.5%
Q1 24
36.6%
Operating Margin
ARWR
ARWR
PLAB
PLAB
Q4 25
15.5%
Q3 25
22.9%
Q2 25
26.4%
Q1 25
24.6%
Q4 24
25.1%
Q3 24
24.7%
Q2 24
25.8%
Q1 24
26.6%
Net Margin
ARWR
ARWR
PLAB
PLAB
Q4 25
11.7%
Q3 25
10.9%
Q2 25
4.2%
Q1 25
20.2%
Q4 24
15.2%
Q3 24
16.3%
Q2 24
16.7%
Q1 24
12.1%
EPS (diluted)
ARWR
ARWR
PLAB
PLAB
Q4 25
$0.22
Q3 25
$0.39
Q2 25
$0.15
Q1 25
$0.68
Q4 24
$0.54
Q3 24
$0.55
Q2 24
$0.58
Q1 24
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARWR
ARWR
PLAB
PLAB
Cash + ST InvestmentsLiquidity on hand
$715.0M
$575.8M
Total DebtLower is stronger
$16.0K
Stockholders' EquityBook value
$568.4M
$1.1B
Total Assets
$1.6B
$1.8B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARWR
ARWR
PLAB
PLAB
Q4 25
$715.0M
Q3 25
$575.8M
Q2 25
$558.4M
Q1 25
$642.2M
Q4 24
$640.7M
Q3 24
$606.4M
Q2 24
$559.9M
Q1 24
$521.5M
Total Debt
ARWR
ARWR
PLAB
PLAB
Q4 25
Q3 25
$16.0K
Q2 25
$19.0K
Q1 25
$21.0K
Q4 24
$25.0K
Q3 24
$28.0K
Q2 24
$2.5M
Q1 24
$2.7M
Stockholders' Equity
ARWR
ARWR
PLAB
PLAB
Q4 25
$568.4M
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$1.1B
Q2 24
$1.0B
Q1 24
$1.0B
Total Assets
ARWR
ARWR
PLAB
PLAB
Q4 25
$1.6B
Q3 25
$1.8B
Q2 25
$1.7B
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.6B
Debt / Equity
ARWR
ARWR
PLAB
PLAB
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARWR
ARWR
PLAB
PLAB
Operating Cash FlowLast quarter
$13.5M
$50.1M
Free Cash FlowOCF − Capex
$11.3M
$25.2M
FCF MarginFCF / Revenue
4.3%
12.0%
Capex IntensityCapex / Revenue
0.8%
11.8%
Cash ConversionOCF / Net Profit
0.44×
2.19×
TTM Free Cash FlowTrailing 4 quarters
$64.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARWR
ARWR
PLAB
PLAB
Q4 25
$13.5M
Q3 25
$50.1M
Q2 25
$31.5M
Q1 25
$78.5M
Q4 24
$68.4M
Q3 24
$75.1M
Q2 24
$76.5M
Q1 24
$41.5M
Free Cash Flow
ARWR
ARWR
PLAB
PLAB
Q4 25
$11.3M
Q3 25
$25.2M
Q2 25
$-29.1M
Q1 25
$43.3M
Q4 24
$25.2M
Q3 24
$50.7M
Q2 24
$56.5M
Q1 24
$-1.8M
FCF Margin
ARWR
ARWR
PLAB
PLAB
Q4 25
4.3%
Q3 25
12.0%
Q2 25
-13.8%
Q1 25
20.4%
Q4 24
11.3%
Q3 24
24.0%
Q2 24
26.0%
Q1 24
-0.8%
Capex Intensity
ARWR
ARWR
PLAB
PLAB
Q4 25
0.8%
Q3 25
11.8%
Q2 25
28.7%
Q1 25
16.6%
Q4 24
19.4%
Q3 24
11.6%
Q2 24
9.2%
Q1 24
20.0%
Cash Conversion
ARWR
ARWR
PLAB
PLAB
Q4 25
0.44×
Q3 25
2.19×
Q2 25
3.55×
Q1 25
1.83×
Q4 24
2.02×
Q3 24
2.18×
Q2 24
2.11×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARWR
ARWR

Segment breakdown not available.

PLAB
PLAB

High End Integrated Circuits$53.6M25%
High End Flat Panel Displays$53.5M25%
KR$43.7M21%
Other$42.1M20%
Mainstream Flat Panel Displays$9.1M4%
Transferred At Point In Time$8.4M4%

Related Comparisons